

Financial news for ATNM dated on 2020-06-05: 77 Biggest Movers From Yesterday

Financial news for ATNM dated on 2020-06-04: 60 Stocks Moving In Thursday's Mid-Day Session

Financial news for ATNM dated on 2020-06-04: Actinium Pharmaceuticals shares are trading higher after H.C. Wainwright initiated coverage on the company's stock with a Buy rating and announced a \$3 price target.

Financial news for ATNM dated on 2020-06-04: H.C. Wainwright Initiates Coverage On Actinium Pharmaceuticals with Buy Rating, Announces Price Target of \$3

Financial news for ATNM dated on 2020-05-01: Sabby Management Llc Reports 7.29% Passive Stake in Actinium Pharmaceuticals as of April 22

Financial news for ATNM dated on 2020-04-23: 70 Biggest Movers From Yesterday

Financial news for ATNM dated on 2020-04-22: Mid-Afternoon Market Update: Dow Climbs 450 Points; American Eagle Outfitters Shares Slide

Financial news for ATNM dated on 2020-04-22: 46 Stocks Moving In Wednesday's Mid-Day Session

Financial news for ATNM dated on 2020-04-22: Mid-Day Market Update: Crude Oil Jumps 25%; VBI Vaccines Shares Plunge

Financial news for ATNM dated on 2020-04-22: Mid-Morning Market Update: Markets Open Higher; Kimberly-Clark Beats Q1 Expectations

Financial news for ATNM dated on 2020-04-22: The Daily Biotech Pulse: Immunic To Develop COVID Treatment, Gilead Strikes IO Partnership

Financial news for ATNM dated on 2020-04-22: 32 Stocks Moving in Wednesday's Pre-Market Session

Financial news for ATNM dated on 2020-04-22: Actinium Pharmaceuticals Prices 183M Share Public Offering @\$0.15/Share

Financial news for ATNM dated on 2020-04-21: Actinium Pharmaceuticals, Inc. Announces Proposed Public Offering; Terms Not Disclosed

Financial news for ATNM dated on 2020-04-16: Actinium Reports Single Ad Hoc Interim Analysis For SIERRA Trial Will Be Exercised At Co.'s Discretion In Q2'20, Sees Topline Data Results Available In Q4'20

Financial news for ATNM dated on 2020-03-05: Actinium Pharma Reports First Patient Treated In Third, Final Dose Cohort Of Actimab-A CLAG-M Combo Phase 1 Trial In ACute Myeloid Leukemia

Financial news for ATNM dated on 2020-02-26: Actinium Announces Actimab-A Plus 7+3 Combination Trial For Newly Diagnosed Acute Myeloid Leukemia Patients

Financial news for ATNM dated on 2020-02-21: Actinium Highlights Presentation Of Findings From Mid-Point Analysis Of Pivotal SIERRA Trial Of Iomab-B At 2020 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

Financial news for ATNM dated on 2020-01-13: Actinium Pharmaceuticals Announces Iomab-ACT Program Gene Therapy Collaboration with UC Davis in Ongoing Clinical Trial for Patients with HIV-Related Lymphoma

Financial news for ATNM dated on 2019-12-09: Actinium Pharmaceuticals Highlights 86% Response Rate and 71% MRD Negative Rate in Actimab-A CLAG-M Combination Trial in Patients with Relapsed or Refractory AML at ASH 2019 Annual Meeting

Financial news for ATNM dated on 2019-12-09: Actinium Pharma to Advance Low Dose Iodine-131 As an Alternative to Standard Chemotherapy

Financial news for ATNM dated on 2019-12-07: The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling

Financial news for ATNM dated on 2019-12-01: The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More

Financial news for ATNM dated on 2019-11-18: Actinium Pharmaceuticals shares are trading lower. Not seeing any news to justify the price action.

Financial news for ATNM dated on 2019-11-06: Actinium Pharmaceuticals To Present New Clinical Findings From SIERRA Trial Supporting The Iomab-ACT Program For Targeted Lymphodepletion For CAR-T And Adoptive Cell Therapies At ASH 2019 Dec. 7-10

Financial news for ATNM dated on 2019-10-31: Actinium Pharmaceuticals shares are trading higher. Not seeing any news to justify the price action.

Financial news for ATNM dated on 2019-10-29: 46 Biggest Movers From Yesterday

Financial news for ATNM dated on 2019-10-28: Mid-Afternoon Market Update: Crude Oil Down Over 1%; Liberty Property Trust Shares Spike Higher

Financial news for ATNM dated on 2019-10-28: 40 Stocks Moving In Monday's Mid-Day Session

Financial news for ATNM dated on 2019-10-28: Mid-Day Market Update: Spotify Jumps Following Q3 Earnings; PG&E Shares Plummet

Financial news for ATNM dated on 2019-10-28: Mid-Morning Market Update: Markets Open Higher; Walgreens Boots Alliance Earnings Beat Estimates

Financial news for ATNM dated on 2019-10-28: Actinium Pharmaceuticals shares are trading lower after the company reported results from the pivotal Iomab-B Phase 3 SIERRA trial.

Financial news for ATNM dated on 2019-10-28: Actinium Announces 'Positive' Interim Results from Iomab-B Pivotal Phase 3 SIERRA Trial

Financial news for ATNM dated on 2019-10-27: The Week Ahead In Biotech: Adcom Test For Agile; Pfizer, Merck Lead Earnings

Financial news for ATNM dated on 2019-08-06: The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering

Financial news for ATNM dated on 2019-07-23: Actinium Achieves Fifty Percent Enrollment In Pivotal Phase 3 SIERRA Trial For Iomab-B

Financial news for ATNM dated on 2019-07-11: Actinium Pharma Highlights 2 Presentations At Health Physics Society Annual Meeting Show Support For Profile Of Iomab-B For SIERRA Trial Caregivers

Financial news for ATNM dated on 2019-06-25: Actinium Highlights Presentation Of New Data Demonstrating Effective Lymphodepletion With Lutetium-177 For CAR-T At The 2019 Society Of Nuclear Medicine And Molecular Imaging Annual Meeting

Financial news for ATNM dated on 2019-06-14: The Daily Biotech Pulse: Hematology And Rheumatology Conference Presentations Take The Spotlight, Eton In-Licenses Epilepsy Drug NDA

Financial news for ATNM dated on 2019-06-01: The Week Ahead In Biotech: ASCO Presentations Pick Up The Pace

Financial news for ATNM dated on 2019-05-16: Actinium Pharma Highlights Abstract Related To Iomab-B To Be Presented At ASCO

Financial news for ATNM dated on 2019-04-22: 54 Biggest Movers From Thursday

Financial news for ATNM dated on 2019-04-18: Mid-Afternoon Market Update: Pier 1 Imports Falls On Downbeat Q4 Results; Mustang Bio Shares Climb

Financial news for ATNM dated on 2019-04-18: 48 Stocks Moving In Thursday's Mid-Day Session

Financial news for ATNM dated on 2019-04-18: Mid-Day Market Update: Dow Up Over 100 Points; Actinium Pharmaceuticals Shares Plunge

Financial news for ATNM dated on 2019-04-18: Sabby Management Reports 8.02% Passive Stake In Actinium Pharmaceuticals

Financial news for ATNM dated on 2019-04-18: Actinium Pharma shares are trading lower after the company priced a 43M share common stock offering at \$0.385 per share.

Financial news for ATNM dated on 2019-04-18: Actinium Pharmaceuticals Prices 42.86M Share Common Stock Offering At \$0.385/Share

Financial news for ATNM dated on 2019-04-18: 31 Stocks Moving In Thursday's Pre-Market Session

Financial news for ATNM dated on 2019-04-17: Actinium Pharmaceuticals shares are trading lower after the company reported a proposed common stock offering.

Financial news for ATNM dated on 2019-04-17: Actinium Pharmaceuticals Reports Proposed Common Stock Offering; Size Not Disclosed

Financial news for ATNM dated on 2019-04-08: Actinium Pharma Highlights Presentation Of 2 Oral, 4 Poster Presentations For AWE At Targeted-Alpha-Therapy International Symposium

Financial news for ATNM dated on 2019-04-02: The Daily Biotech Pulse: FDA Nod For ADMA, Regulatory Setback For Apyx, Achieve Life Sciences Smoking Cessation Drug Trial

Financial news for ATNM dated on 2019-03-30: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs

Financial news for ATNM dated on 2019-03-20: Actinium Reports Novel Combo Of Actimab-A, Venetoclax Accepted For Poster Presentation At AACR Meeting

Financial news for ATNM dated on 2019-02-22: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs

Financial news for ATNM dated on 2019-02-15: Centers For Medicaid, Medicare Has Proposed Coverage With Evidence Development For CAR-T Therapy, Decision Would Provide Nationwide Consistency In CMS Coverage

Financial news for ATNM dated on 2019-02-06: Actinium Offers Update On Patent Portfolio For its Iomab-ACT Next-Generation CAR-T Lymphodepletion Program

Financial news for ATNM dated on 2019-02-04: Actinium Initiates Second Dosing Cohort of Novel Combination Trial with Actimab-A and CLAG-M Salvage Regimen at Medical College of Wisconsin

Financial news for ATNM dated on 2019-01-17: Actinium Completes First Module of Collaborative Research Program with Astellas, Second Module Initiated

Financial news for ATNM dated on 2018-12-03: Actinium Highlights Post Presentation Of Actimab-A Phase 2 Trial In Older Patients With Unfit AML At ASH, Showed 'Single Agent Activity of the CD33 Antibody Radiation Conjugate'

Financial news for ATNM dated on 2018-12-02: The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs

Financial news for ATNM dated on 2018-10-31: The Daily Biotech Pulse: KemPharm, FDA Nod For Merck, Clovis Q3 Miss, 3 Stocks To Debut

Financial news for ATNM dated on 2018-10-01: Actinium Reports Launch Of Iomab-ACT Program Offering Its Targeted, Chemo-Free, Lymphodepletion Technology As Universal Solution To CAR-T Product Developers

Financial news for ATNM dated on 2018-09-27: Stocks Which Set New 52-Week High Yesterday, September 26th

Financial news for ATNM dated on 2018-06-28: Actinium Announces New Clinical Trial to Study Effect of Actimab-A on Minimal Residual Disease in Postremission AML Patients

Financial news for ATNM dated on 2018-06-26: UPDATE: Actinium Pharmaceuticals Says Iomab-b Remains The Only Targeted Conditioning Treatment In Clinical Trials With The Potential To Increase Access To And Improve Outcomes Of Bone Marrow Transplant

Financial news for ATNM dated on 2018-06-26: Actinium Pharmaceuticals Announces Dosing Of 38th Patient And 25 Percent Enrollment In Iomab-B Pivotal SIERRA Trial

Financial news for ATNM dated on 2018-06-13: Actinium Pharma Reports Treatment Of First Patient In Novel Combination Trial Of Actimab-A Plus CLAG-M

Financial news for ATNM dated on 2018-03-28: Actinium Pharma Reports Collaborative Research Partnership With Astellas

Financial news for ATNM dated on 2018-03-13: Actinium Announces FDA Clearance of IND For Phase 1 trial of Actimab-A in Combination with CLAG-M for Patients with Relapsed or Refractory AML

Financial news for ATNM dated on 2018-03-05: Actinium Pharma Expects \$15.4M of Proceeds From its Rights Offering

Financial news for ATNM dated on 2018-02-28: Actinium Pharma Reports Progress At BMT Tandem Meetings: 'Protocol changes to the control arm of the pivotal Phase 3 trial for Iomab-B well received'

Financial news for ATNM dated on 2018-02-27: 38 Biggest Movers From Yesterday

Financial news for ATNM dated on 2018-02-26: Mid-Afternoon Market Update: Telaria Falls Following Q4 Results; Achillion Pharmaceuticals Shares Surge

Financial news for ATNM dated on 2018-02-26: 28 Stocks Moving In Monday's Mid-Day Session

Financial news for ATNM dated on 2018-02-26: Actinium Pharmaceuticals Prices 50M Unit Offering At Subscription Price Of \$0.50/Unit

Financial news for ATNM dated on 2018-02-12: Actinium Announces Submission of IND For Actimab-A in Combination with CLAG-M for Patients with Relapsed or Refractory AML

Financial news for ATNM dated on 2018-02-06: Actinium Pharma Reports Trial To Study Actimab-A In Combo With CLAG-M For Relapse, Refractory AML Patients

Financial news for ATNM dated on 2018-02-01: Actinium Pharma Announces Rights Offering

Financial news for ATNM dated on 2018-02-01: Actinium Pharma Reports Acceptance Of Abstract For AACR Highlighting Superior In Vivo Survival Data for Actinium Labelled Daratumumab Versus Unlabeled Daratumumab

Financial news for ATNM dated on 2018-01-25: Actinium Pharmaceuticals Issues Company Update and Outlook for 2018

Financial news for ATNM dated on 2018-01-25: Actinium Pharmaceuticals Issues Letter to Investors Providing Company Update and Outlook for 2018

Financial news for ATNM dated on 2017-12-12: Actinium Pharma Gives an Update From its AWE Program

Financial news for ATNM dated on 2017-12-11: Actinium Highlights Data Presented At ASH Showing CD33 Expression In Significant Number of Multiple Myeloma Patients Supporting Rationale For Actimab-M

Financial news for ATNM dated on 2017-12-11: Actinium Pharma Offers Prelim. Results From Phase 2 Trial For Actimab-A At ASH: '69% Overall Response Rate and 98% median reduction in bone marrow blasts reported with Actimab-A given at 2.0 uCi/kg/fraction as a single agent'

Financial news for ATNM dated on 2017-12-06: B. Riley Initiates Coverage On Actinium Pharmaceuticals with Buy Rating, Announces \$2.75 Price Target

Financial news for ATNM dated on 2017-12-05: Actinium Pharmaceuticals Announces Planned Phase 2 Trial in Myelodysplastic Syndromes Targeted at Patients with High-Risk p53+ Genetic Mutations

Financial news for ATNM dated on 2017-10-26: Secondary Offering Lockup Expirations Today For Karmada and Actinium Pharma

Financial news for ATNM dated on 2017-10-25: Actinium Pharma Reports Activation Of 15th Clinical Trial Site In Phase 3 SIERRA Trial For Iomab-B

Financial news for ATNM dated on 2017-10-23: The Week Ahead: Earnings Season Starts In Earnest

Financial news for ATNM dated on 2017-10-04: Actinium Pharma Says Expecting Interim Actimab-A Phase 2 Data in 2017, Top Line Data in 1H 2018

Financial news for ATNM dated on 2017-10-04: Actinium Pharmaceuticals Says Phase 2 Clinical Trial Is Currently Active At 16 Clinical Trial Sites, Surpassing 10 Clinical Sites That Were Planned For The Trial

Financial news for ATNM dated on 2017-07-28: Mid-Afternoon Market Update: CyberOptics Drops After Q2 Results; Aaron's Shares Surge

Financial news for ATNM dated on 2017-07-28: 20 Biggest Mid-Day Losers For Friday

Financial news for ATNM dated on 2017-07-28: Mid-Day Market Update: Boston Beer Surges On Earnings Beat; Destination Maternity Shares Slide

Financial news for ATNM dated on 2017-07-28: Actinium Prices Offering Of 21.5M Shares At \$0.75/Share, Related Warrant

Financial news for ATNM dated on 2017-07-28: 22 Stocks Moving In Friday's Pre-Market Session

Financial news for ATNM dated on 2017-06-15: Actinium Pharmaceuticals Says Iomab-B Phase 3 SIERRA Trial Is Accelerating With Number Of Clinical Trial Sites Increasing

Financial news for ATNM dated on 2017-06-09: Actinium Pharmaceuticals Names Sandesh Seth CEO

Financial news for ATNM dated on 2017-05-24: Actinium Pharmaceuticals Granted Orphan Designation from the EMA for Actimab-A

Financial news for ATNM dated on 2017-05-10: Actinium Pharma Reports Received Clearance from Health Canada to Initiate Pivotal Phase 3 SIERRA Trial of Iomab-B

Financial news for ATNM dated on 2017-03-21: Actinium Gets Regulatory Pathway for EU Approval of Iomab-B, Trial Design and Primary Endpoint Acceptable as Basis for Marketing Authorization Application

Financial news for ATNM dated on 2017-02-07: Actinium Pharmaceuticals Reports Pipeline Expansion with Initiation of Clinical Trial of Actimab-M in Multiple Myeloma

Financial news for ATNM dated on 2016-12-13: Actinium Pharma has Submitted an Application with the European Medicines Agency Seeking Orphan Designation for Actimab-A

Financial news for ATNM dated on 2016-12-05: Actinium Highlights Results from Phase 1 Clinical Trial of Actimab-A at ASH 2016

Financial news for ATNM dated on 2016-11-22: Actinium Pharma Expects to Report Interim Phase 2 Data by Mid 2017

Financial news for ATNM dated on 2016-10-26: Actinium Pharmaceuticals Announces New Hires As Supply Chain Organization Expands To Accommodate Growth

Financial news for ATNM dated on 2016-10-25: Actinium Pharma Reports Initiation of Pursuit of Scientific Advice for Iomab-B from EMA

Financial news for ATNM dated on 2016-10-18: Actinium Pharmaceuticals Granted Orphan Designation from the European Medicines Agency for Iomab-B

Financial news for ATNM dated on 2016-09-29: Mid-Afternoon Market Update: Dow Falls Over 200 Points; Catabasis Shares Spike Higher

Financial news for ATNM dated on 2016-09-29: 12 Biggest Mid-Day Losers For Thursday

Financial news for ATNM dated on 2016-09-29: Mid-Day Market Update: Crude Oil Rises Over 2%; Intra-Cellular Therapies Shares Slide

Financial news for ATNM dated on 2016-09-29: Mid-Morning Market Update: Markets Edge Lower; PepsiCo Beats Q3 Expectations

Financial news for ATNM dated on 2016-09-29: 15 Stocks Moving In Thursday's Pre-Market Session

Financial news for ATNM dated on 2016-09-29: Actinium Prices 8M Shares At \$1.25/Share

Financial news for ATNM dated on 2016-09-28: Actinium Reports Offering of Common Shares

Financial news for ATNM dated on 2016-09-27: 15 Biggest Mid-Day Losers For Tuesday

Financial news for ATNM dated on 2016-09-27: Actinium Pharma Shares Down 9% Amid Profit Taking; Stock Up 20+% Since Sept. 21

Financial news for ATNM dated on 2016-09-27: Actinium Reports Initiation of Phase 2 Trial of Actimab-A in Patients Newly Diagnosed with Acute Myeloid Leukemia Over Age 60

Financial news for ATNM dated on 2016-08-25: Benzinga's Top Initiations

Financial news for ATNM dated on 2016-08-25: Roth Capital Initiates Coverage on Actinium Pharmaceuticals at Buy, Announces \$5.00 PT

Financial news for ATNM dated on 2016-08-04: Actinium Pharmaceuticals Issues Mid-Year Letter to Shareholders Providing Update on Company Progress and Anticipated Milestones

Financial news for ATNM dated on 2016-07-20: Actinium Pharma Announces Successful Meeting With Investigators For Phase 3 Iomab-BSIERRA Trial

Financial news for ATNM dated on 2016-06-29: Actinium Pharmaceuticals Starts Pivotal Phase 3 SIERRA Trial

Financial news for ATNM dated on 2016-06-01: 7 Big Pre-Market Gainers

Financial news for ATNM dated on 2016-06-01: Actinium Pharmaceuticals Announces Positive Safety and Efficacy Results From Phase 1 Actimab-A Trial in Patients With Newly Diagnosed Acute Myeloid Leukemia

Financial news for ATNM dated on 2016-04-12: Actinium Reports Selection of Zevacor Pharma for Clinical Production, Supply of Lomab-B for Pivotal Phase 3 SIERRA Trial

Financial news for ATNM dated on 2016-03-30: Actinium Receives Orphan Drug Designation From FDA for Iomab-B in Treating Refractory and Relapsed Acute Myeloid Leukemia in Elderly Patients

Financial news for ATNM dated on 2016-03-08: Actinium Pharmaceuticals Files Provisional Patent Application Related to Commercial Scale Labeling and Processes for Iomab-B

Financial news for ATNM dated on 2016-03-02: Actinium Pharmaceuticals Selects Medpace Inc. as Clinical Research Organization for Pivotal Phase 3 Iomab-B Trial

Financial news for ATNM dated on 2016-02-29: H.C. Wainwright Initiates Coverage on Actinium Pharmaceuticals at Buy, Announces \$8.00 PT

Financial news for ATNM dated on 2016-01-07: Napodano: Here Is Actinium's Place Among The CAR-T Hype & Radiopharma Busts

Financial news for ATNM dated on 2015-12-24: Actinium Pharma Reports Deal with Memorial Sloan Kettering Cancer Center Related to Certain Liquidity Matters

Financial news for ATNM dated on 2015-12-17: Actinium Reports Iomab-B IND Has Been Cleared By FDA; Pivotal, Phase 3 Trial to Proceed

Financial news for ATNM dated on 2015-12-08: Actinium Pharma Reports Trial Results for Actimab-A Presented at ASH

Financial news for ATNM dated on 2015-11-23: Actinium Reports Filing of Orphan Drug App for US of Iomab-B in Treating Refractory, Relapsed AML in Elderly Patients

Financial news for ATNM dated on 2015-11-17: Actinium Submits IOMAB-B IND Application to FDA; Pending FDA Acceptance, Co to Initiate Single, Pivotal Phase 3 Clinical Study In Refractory AML Patients Age 55+

Financial news for ATNM dated on 2015-10-15: FBR Capital Initiates Coverage on Actinium Pharmaceuticals at Outperform, Announces \$12.00 PT

Financial news for ATNM dated on 2015-08-10: Morning Market Gainers

Financial news for ATNM dated on 2015-08-05: Actinium Letter to Shareholders Outlining Measures to Move Iomab-B and Actimab-A Into Advanced Development

Financial news for ATNM dated on 2015-07-15: US Stock Futures Edge Higher; Bank of America Earnings In Focus

Financial news for ATNM dated on 2015-07-15: Actinium Advances Iomab-B Towards Phase 3 With Pre-IND Meeting Request

Financial news for ATNM dated on 2015-06-24: Actinium Reports Filing of Provisional Patent Application for Infusion Administration of Iomab-B

Financial news for ATNM dated on 2015-06-19: Actinium Pharmaceuticals Shares Spike Higher on Report by Technology Profits Confidential

Financial news for ATNM dated on 2015-06-04: Actinium Pharmaceuticals to Issue Aggregate Of 1.9M Shares of Common Stock @\$2.60/Share

Financial news for ATNM dated on 2015-06-04: Actinium Pharmaceuticals Halted; Pending News

Financial news for ATNM dated on 2015-06-04: Actinium's Clinical Data Generates Large Interest at 2015 ASCO Annual Meeting

Financial news for ATNM dated on 2015-05-28: Actinium Offers Clinical Update on Actimab-A Provided at Targeted Alpha Therapy Symposium

Financial news for ATNM dated on 2015-05-28: Actinium Pharmaceuticals Says Provided Clinical Update on Ongoing Phase I/II Study of Actimab-A, Company's Alpha-Emitting Radiolabeled Antibody

Financial news for ATNM dated on 2015-05-20: Actinium to Provide Clinical Update on

Actimab-A at Upcoming 2015 ASCO Annual Meeting

Financial news for ATNM dated on 2015-04-15: Actinium Doses the Initial Patient in the Fourth, Final Cohort of Its Actimab-A Trial

Financial news for ATNM dated on 2015-03-18: UPDATE: 2 Of 3 Actinium Patients Showed Complete Remission During Ongoing Trials

Financial news for ATNM dated on 2015-03-18: Actinium Announces New Data From Current Phase 1/2 Trial of Actimab-A Demonstrating Safety and Robust Clinical Efficacy in High Risk Elderly Acute Myeloid Leukemia Patients

Financial news for ATNM dated on 2015-02-06: Morning Market Losers

Financial news for ATNM dated on 2015-02-06: Actinium Prices Public Offering of Common Stock and Warrants to Purchase Common Stock

Financial news for ATNM dated on 2015-02-05: Actinium Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock

Financial news for ATNM dated on 2015-01-26: Actinium Submits Pre-IND Meeting Request to the U.S. FDA for its Iomab-B Drug Candidate

Financial news for ATNM dated on 2015-01-20: Actinium Submits CMC Meeting Request to FDA for Iomab-B to Support IND Filing and Anticipated Commencement of Phase 3 Trial in Mid-2015

Financial news for ATNM dated on 2014-12-01: Actinium Receives Orphan-Drug Designation For Actimab-A

Financial news for ATNM dated on 2014-11-26: Actinium Pharma's AML Treatment Receives Orphan Designation From FDA

Financial news for ATNM dated on 2014-11-06: Actinium Pharmaceuticals Actimab-A Phase I/II Trial Interim Data Demonstrate Extension of Overall Survival to 9.1 Months in Elderly Secondary Acute Myeloid Leukemia

Financial news for ATNM dated on 2014-10-01: MLV & Co. Initiates Coverage on Actinium Pharmaceuticals Inc at Buy, Announces \$16.00 PT

Financial news for ATNM dated on 2014-09-03: Actinium Files Orphan Drug Application for Actimab-A in Treatment of Newly Diagnosed Acute Myeloid Leukemia in Elderly Patients

Financial news for ATNM dated on 2014-08-12: Actinium Pharmaceuticals Inc Reports Q2 EPS of \$0.10

Financial news for ATNM dated on 2014-07-22: Benzinga's Top Initiations

Financial news for ATNM dated on 2014-07-22: Canaccord Genuity Initiates Actinium Pharmaceuticals At Buy

Financial news for ATNM dated on 2014-07-22: Canaccord Genuity Initiates Coverage on Actinium Pharmaceuticals Inc at Buy, Announces \$16.00 PT

Financial news for ATNM dated on 2014-07-07: Actinium Pharma Announces Yair Levy of Baylor to Scientific Advisory Board